Showing 3 of 3 posts
August 25, 2020 | Blogs
COVID-19 has presented an abundance of short-term implications and challenges for biopharma companies; however, it is useful to understand and prepare for the longer-term impacts as the acute disruptions to regulatory processes and healthcare delivery begin to subside. To proactively prepare for a post-COVID-19 world, biopharma leaders should develop strategies to integrate technology across the value chain and increase focus on patient centricity in terms of process flows and treatment administration.
April 29, 2020 | Blogs
Cumulative costs from patient enrollment scenarios due to COVID-19 will likely generate a significant financial drain on biopharma R&D expenditures. CBPartners' blog post investigates this impact and explores mitigation strategies.
April 14, 2020 | Blogs
Disruption in healthcare systems across Europe is rife due to the COVID-19 pandemic, with increasingly strained budgets, and shifting healthcare priorities.